Drug Landscape ›
Enzyme replacement ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Anaemia — 2 reports (18.18%) Abdominal Distension — 1 report (9.09%) Abdominal Sepsis — 1 report (9.09%) Acidosis — 1 report (9.09%) Acquired Aminoaciduria — 1 report (9.09%) Beta 2 Microglobulin Urine Increased — 1 report (9.09%) Blood Calcium Decreased — 1 report (9.09%) Blood Phosphorus Decreased — 1 report (9.09%) Blood Uric Acid Decreased — 1 report (9.09%) Body Fat Disorder — 1 report (9.09%)
Source database →
Enzyme replacement in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Enzyme replacement approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Enzyme replacement in United States?
Rigshospitalet, Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.